86 related articles for article (PubMed ID: 8104585)
1. Fe(III)-EHPG and Fe(III)-5-Br-EHPG as contrast agents in MRI: an animal study.
Liu GC; Wang YM; Jaw TS; Chen HM; Sheu RS
J Formos Med Assoc; 1993 Apr; 92(4):359-66. PubMed ID: 8104585
[TBL] [Abstract][Full Text] [Related]
2. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
J Comput Assist Tomogr; 1985; 9(3):431-8. PubMed ID: 3989032
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of Fe-(5-C2H5-EHPG)- as a contrast agent in MR imaging of hepatobiliary system.
Sheu RS; Liu GC; Wang YM; Jaw TS; Chen HM; Kuo YT
Kaohsiung J Med Sci; 1997 Feb; 13(2):75-85. PubMed ID: 9099045
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents.
Hoener B; Engelstad BL; Ramos EC; Macapinlac HA; Price DC; Johnson TR; White DL
J Magn Reson Imaging; 1991; 1(3):357-62. PubMed ID: 1802149
[TBL] [Abstract][Full Text] [Related]
5. Hepatobiliary MR contrast agents: 5-substituted iron-EHPG derivatives.
Lauffer RB; Vincent AC; Padmanabhan S; Villringer A; Saini S; Elmaleh DR; Brady TJ
Magn Reson Med; 1987 Jun; 4(6):582-90. PubMed ID: 3613958
[TBL] [Abstract][Full Text] [Related]
6. EHPG iron(III) complexes as potential contrast contrast agents for MRI.
Kuźnik N; Jewuła P; Oczek L; Kozłowicz S; Grucela A; Domagała W
Acta Chim Slov; 2014; 61(1):87-93. PubMed ID: 24664331
[TBL] [Abstract][Full Text] [Related]
7. Investigation of physicochemical and in-vivo behavior of diastereomeric iron-59, gallium-68, and indium-111-EHPG trivalent metal complexes.
Madsen SL; Bannochie CJ; Martell AE; Mathias CJ; Welch MJ
J Nucl Med; 1990 Oct; 31(10):1662-8. PubMed ID: 2213190
[TBL] [Abstract][Full Text] [Related]
8. UV and fluorescence spectral changes induced by neodymium binding of N,N'-ethylenebis[2-(o-hydroxyphenolic)glycine] and N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N' diacetic acid.
Wang Z; Yang B
Spectrochim Acta A Mol Biomol Spectrosc; 2006 Nov; 65(3-4):946-9. PubMed ID: 16684618
[TBL] [Abstract][Full Text] [Related]
9. Site-specific water proton relaxation enhancement of iron(III) chelates noncovalently bound to human serum albumin.
Jenkins BG; Armstrong E; Lauffer RB
Magn Reson Med; 1991 Jan; 17(1):164-78. PubMed ID: 1648652
[TBL] [Abstract][Full Text] [Related]
10. MR imaging of blood-borne liver metastases in mice: contrast enhancement with Fe-EHPG.
Shtern F; Garrido L; Compton C; Swiniarski JK; Lauffer RB; Brady TJ
Radiology; 1991 Jan; 178(1):83-9. PubMed ID: 1984329
[TBL] [Abstract][Full Text] [Related]
11. Pulse sequence optimization for MR imaging using a paramagnetic hepatobiliary contrast agent.
Greif WL; Buxton RB; Lauffer RB; Saini S; Stark DD; Wedeen VJ; Rosen BR; Brady TJ
Radiology; 1985 Nov; 157(2):461-6. PubMed ID: 4048456
[TBL] [Abstract][Full Text] [Related]
12. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
Int J Rad Appl Instrum B; 1988; 15(1):47-9. PubMed ID: 3350696
[No Abstract] [Full Text] [Related]
13. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
Hershko C; Grady RW; Link G
Haematologia (Budap); 1984; 17(1):25-33. PubMed ID: 6427069
[TBL] [Abstract][Full Text] [Related]
14. Fe-HBED Analogs: A Promising Class of Iron-Chelate Contrast Agents for Magnetic Resonance Imaging.
Bales BC; Grimmond B; Johnson BF; Luttrell MT; Meyer DE; Polyanskaya T; Rishel MJ; Roberts J
Contrast Media Mol Imaging; 2019; 2019():8356931. PubMed ID: 31969797
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
Hershko C; Grady RW; Link G
Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
[TBL] [Abstract][Full Text] [Related]
16. Oxidative renal tubular injuries induced by aminocarboxylate-type iron (III) coordination compounds as candidate renal carcinogens.
Mizuno R; Kawabata T; Sutoh Y; Nishida Y; Okada S
Biometals; 2006 Dec; 19(6):675-83. PubMed ID: 16670936
[TBL] [Abstract][Full Text] [Related]
17. TMPHPG: a lipophilic derivative of EHPG for iron, gallium-68 and indium-111 hepatobiliary clearance.
Madsen SL; Bannochie CJ; Welch MJ; Mathias CJ; Martell AE
Int J Rad Appl Instrum B; 1991; 18(3):289-94. PubMed ID: 2071441
[TBL] [Abstract][Full Text] [Related]
18. Spectral studies on the interaction between lanthanum ion and the ligand: N,N'-ethylenebis-[2-(o-hydroxyphenolic)glycine].
Yaqin Z; Binsheng Y
Spectrochim Acta A Mol Biomol Spectrosc; 2005 Nov; 62(1-3):641-4. PubMed ID: 16257770
[TBL] [Abstract][Full Text] [Related]
19. Chemical evaluation of HBED/Fe(3+) and the novel HJB/Fe(3+) chelates as fertilizers to alleviate iron chlorosis.
López-Rayo S; Hernández D; Lucena JJ
J Agric Food Chem; 2009 Sep; 57(18):8504-13. PubMed ID: 19689133
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging.
Elizondo G; Fretz CJ; Stark DD; Rocklage SM; Quay SC; Worah D; Tsang YM; Chen MC; Ferrucci JT
Radiology; 1991 Jan; 178(1):73-8. PubMed ID: 1898538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
